Skip To Main Content
Barbara Radecka on Muck Rack

Barbara Radecka

As seen in: Nature, MDPI, ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ddMVAC versus gemcitabine–cisplatin as neoadjuvant treatment for muscle-invasive urothelial bladder cancer: a multicenter real-world study

|
By Mateusz Malik, Dawid Sigorski, Zbyszko Chowaniec, Marek Gełej, Krzysztof Tupikowski, Adam Maciejczyk, Barbara Radecka, Tomasz Lewandowski, Lubomir Bodnar, Rodryg Ramlau, Piotr Jacyk, Jacek Ornat, Katarzyna Czerko, Anna Kopczyńska, Barbara Iwanik, Ewelina Kołodziejska, Radosław Piszczek, Zenona Jabłońska
| Nature Verified
Abstract Cisplatin-based neoadjuvant chemotherapy (NACT) followed by radical cystectomy (RC) is the standard treatment for eligible patients with muscle-invasive bladder cancer (MIBC). However, the comparative effectiveness of gemcitabine/cisplatin (GC) and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in routine practice remains insufficiently defined, particularly in broader real-world populations that include patients with regional lymph node involvement.
Open in Who Shared Issue with article?

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

|
By Radhika Appaya, Qiang Liu, Barbara Radecka, Maria Fernandez Abad
| ONCOLOGY journal Verified
Background The NATALEE trial showed statistically significant and clinically meaningful invasive disease-free survival (iDFS) with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI in patients with stage II/III hormone receptor–positive (HR+)/HER2-negative (HER2–) early breast cancer (EBC; HR, 0.715; 95% CI, 0.609-0.840; 4-year absolute benefit, 4.9%; median follow-up, 44.2 months). We present an exploratory analysis of efficacy in patients with and without dose reduction.
Open in Who Shared Issue with article?

Biomedicines | Free Full-Text | Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil

|
By Aleksandra Jackowska, Mateusz Malik, Barbara Radecka, Marek Gełej
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 3 articles